BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Colonno RJ, Rose R, Baldick CJ, Levine S, Pokornowski K, Yu CF, Walsh A, Fang J, Hsu M, Mazzucco C, Eggers B, Zhang S, Plym M, Klesczewski K, Tenney DJ. Entecavir resistance is rare in nucleoside naïve patients with hepatitis B. Hepatology 2006;44:1656-65. [DOI: 10.1002/hep.21422] [Cited by in Crossref: 270] [Cited by in F6Publishing: 239] [Article Influence: 16.9] [Reference Citation Analysis]
Number Citing Articles
1 Zhang Y, Zhang Y, Kang Y, Wang J, Liu H, Zhu H, Qin Y, Mao R, Lin X, Lu M, Zhang J. Generation of a human hepatoma cell line supporting efficient replication of a lamivudine resistant hepatitis B virus. Journal of Virological Methods 2014;201:51-6. [DOI: 10.1016/j.jviromet.2014.02.008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
2 Zoulim F. Hepatitis B virus resistance to entecavir in nucleoside naïve patients: Does it exist? Hepatology 2006;44:1404-7. [DOI: 10.1002/hep.21451] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 0.9] [Reference Citation Analysis]
3 Oketani M, Uto H, Ido A, Tsubouchi H. Management of hepatitis B virus-related acute liver failure. Clin J Gastroenterol 2014;7:19-26. [PMID: 26183504 DOI: 10.1007/s12328-013-0447-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
4 Lee YB, Lee JH, Choi WM, Cho YY, Yoo JJ, Lee M, Lee DH, Cho Y, Yu SJ, Kim YJ, Yoon JH, Kim CY, Lee HS. Efficacy of adefovir-based combination therapy for patients with Lamivudine- and entecavir-resistant chronic hepatitis B virus infection. Antimicrob Agents Chemother 2013;57:6325-32. [PMID: 24100506 DOI: 10.1128/AAC.01742-13] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
5 Gish RG, Locarnini S. Genotyping and genomic sequencing in clinical practice. Clin Liver Dis 2007;11:761-95, viii. [PMID: 17981228 DOI: 10.1016/j.cld.2007.08.008] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
6 Hofmann WP, Soriano V, Zeuzem S. Antiviral combination therapy for treatment of chronic hepatitis B, hepatitis C, and human immunodeficiency virus infection. Handb Exp Pharmacol 2009;:321-46. [PMID: 19048206 DOI: 10.1007/978-3-540-79086-0_12] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
7 Si Ahmed SN, Zoulim F. Pathobiology of HBV mutants and clinical impact for treatment monitoring. Expert Review of Anti-infective Therapy 2014;7:309-20. [DOI: 10.1586/eri.09.10] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
8 Svicher V, Gori C, Trignetti M, Visca M, Micheli V, Bernassola M, Salpini R, Gubertini G, Longo R, Niero F. The profile of mutational clusters associated with lamivudine resistance can be constrained by HBV genotypes. J Hepatol. 2009;50:461-470. [PMID: 19041149 DOI: 10.1016/j.jhep.2008.07.038] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 2.2] [Reference Citation Analysis]
9 Asan A, Sayan M, Akhan S, Tekin Koruk S, Aygen B, Sirmatel F, Eraksoy H, Tuna N, Köse S, Kaya A, Eren Tulek N, Aktug Demir N, Mistik R, Ormen B, Korkmaz F, Yildirmak T, Ural O, Aydin M, Turgut H, Gunal O, Demirturk N. Molecular Characterization of Drug Resistance in Hepatitis B Viruses Isolated from Patients with Chronical Infection in Turkey. Hepat Mon 2018;18. [DOI: 10.5812/hepatmon.12472] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
10 Zhu Y, Curtis M, Borroto-esoda K. HBV DNA replication mediated by cloned patient HBV reverse transcriptase genes from HBV genotypes A–H and its use in antiviral phenotyping assays. Journal of Virological Methods 2011;173:340-6. [DOI: 10.1016/j.jviromet.2011.03.006] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
11 Davis J. Preventing hepatitis B virus reactivation following immunosuppressive therapy. Internal Medicine Journal 2008;38:617-617. [DOI: 10.1111/j.1445-5994.2008.01652.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
12 Myung HJ, Jeong SH, Kim JW, Kim HS, Jang JH, Lee DH, Kim N, Hwang JH, Park YS, Lee SH. [Efficacy and predictors of the virologic response to entecavir therapy in nucleoside-naive patients with chronic hepatitis B]. Korean J Hepatol 2010;16:57-65. [PMID: 20375643 DOI: 10.3350/kjhep.2010.16.1.57] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
13 Liu BM, Li T, Xu J, Li XG, Dong JP, Yan P, Yang JX, Yan L, Gao ZY, Li WP, Sun XW, Wang YH, Jiao XJ, Hou CS, Zhuang H. Characterization of potential antiviral resistance mutations in hepatitis B virus reverse transcriptase sequences in treatment-naïve Chinese patients. Antiviral Res 2010;85:512-9. [PMID: 20034521 DOI: 10.1016/j.antiviral.2009.12.006] [Cited by in Crossref: 64] [Cited by in F6Publishing: 64] [Article Influence: 4.9] [Reference Citation Analysis]
14 Viganò M, Lampertico P. Antiviral drugs for HBV liver disease. Expert Opin Biol Ther 2011;11:285-300. [PMID: 21204745 DOI: 10.1517/14712598.2011.546340] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
15 Jiang L, Yan LN. Current therapeutic strategies for recurrent hepatitis B virus infection after liver transplantation. World J Gastroenterol 2010; 16(20): 2468-2475 [PMID: 20503446 DOI: 10.3748/wjg.v16.i20.2468] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
16 Zoulim F. Emerging drugs for hepatitis B. Expert Opin Emerg Drugs 2007;12:199-217. [PMID: 17604497 DOI: 10.1517/14728214.12.2.199] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
17 Liaw YF, Gane E, Leung N, Zeuzem S, Wang Y, Lai CL, Heathcote EJ, Manns M, Bzowej N, Niu J, Han SH, Hwang SG, Cakaloglu Y, Tong MJ, Papatheodoridis G, Chen Y, Brown NA, Albanis E, Galil K, Naoumov NV;  GLOBE Study Group. 2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology. 2009;136:486-495. [PMID: 19027013 DOI: 10.1053/j.gastro.2008.10.026] [Cited by in Crossref: 412] [Cited by in F6Publishing: 394] [Article Influence: 29.4] [Reference Citation Analysis]
18 Fournier C, Zoulim F. Antiviral therapy of chronic hepatitis B: prevention of drug resistance. Clin Liver Dis. 2007;11:869-892, ix. [PMID: 17981233 DOI: 10.1016/j.cld.2007.08.013] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 2.3] [Reference Citation Analysis]
19 Akbar SM, Hiasa Y, Mishiro S, Onji M. Treatment of hepatitis B virus-infected patients: utility of therapeutic recommendations in developing countries. Expert Opin Pharmacother 2009;10:1605-14. [PMID: 19496738 DOI: 10.1517/14656560903005579] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
20 Chotiyaputta W, Lok ASF. Hepatitis B virus variants. Nat Rev Gastroenterol Hepatol 2009;6:453-62. [DOI: 10.1038/nrgastro.2009.107] [Cited by in Crossref: 109] [Cited by in F6Publishing: 102] [Article Influence: 8.4] [Reference Citation Analysis]
21 Shirvani-Dastgerdi E, Winer BY, Celià-Terrassa T, Kang Y, Tabernero D, Yagmur E, Rodríguez-Frías F, Gregori J, Luedde T, Trautwein C, Ploss A, Tacke F. Selection of the highly replicative and partially multidrug resistant rtS78T HBV polymerase mutation during TDF-ETV combination therapy. J Hepatol 2017;67:246-54. [PMID: 28392234 DOI: 10.1016/j.jhep.2017.03.027] [Cited by in Crossref: 37] [Cited by in F6Publishing: 30] [Article Influence: 7.4] [Reference Citation Analysis]
22 Zoulim F. [Current data on the treatment of chronic hepatitis B]. Presse Med 2008;37:287-93. [PMID: 18042341 DOI: 10.1016/j.lpm.2007.06.021] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
23 Keating GM. Entecavir: a review of its use in the treatment of chronic hepatitis B in patients with decompensated liver disease. Drugs. 2011;71:2511-2529. [PMID: 22141390 DOI: 10.2165/11208510-000000000-00000] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
24 Santantonio T, Fasano M. Resistance profile of entecavir in patients with chronic hepatitis B. Digestive and Liver Disease Supplements 2008;2:11-5. [DOI: 10.1016/s1594-5804(09)60005-x] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
25 Baqai S, Proudfoot J, Xu R, Kane S, Clark M, Gish R. Comparable efficacy with entecavir monotherapy and tenofovir-entecavir combination in chronic hepatitis B patients. BMJ Open Gastroenterol 2015;2:e000030. [PMID: 26462281 DOI: 10.1136/bmjgast-2015-000030] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
26 Qiu L, Chen L, Chen K. Antihepatitis B therapy: a review of current medications and novel small molecule inhibitors. Fundam Clin Pharmacol 2014;28:364-81. [DOI: 10.1111/fcp.12053] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
27 Sun J, Hou JL, Xie Q, Li XH, Zhang JM, Wang YM, Wang H, Lai JY, Chen SJ, Jia JD, Sheng JF, Chan HL, Wang JF, Li MK, Jiang M, Popescu M, Sung JJ. Randomised clinical trial: efficacy of peginterferon alfa-2a in HBeAg positive chronic hepatitis B patients with lamivudine resistance. Aliment Pharmacol Ther. 2011;34:424-431. [PMID: 21692822 DOI: 10.1111/j.1365-2036.2011.04750.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
28 Scott LJ, Keating GM. Entecavir: a review of its use in chronic hepatitis B. Drugs. 2009;69:1003-1033. [PMID: 19496629 DOI: 10.2165/00003495-200969080-00005] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
29 Kim KH, Kim ND, Seong BL. Discovery and development of anti-HBV agents and their resistance. Molecules. 2010;15:5878-5908. [PMID: 20802402 DOI: 10.3390/molecules15095878] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 3.3] [Reference Citation Analysis]
30 Zhang Y, He S, Li Q, Guo J. Dynamics of hepatitis B virus resistance substitutions correlates with virological response in lamivudine-refractory patients with entecavir rescue monotherapy. Virus Research 2013;177:156-62. [DOI: 10.1016/j.virusres.2013.08.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
31 Locarnini S, Bowden S. Drug Resistance in Antiviral Therapy. Clinics in Liver Disease 2010;14:439-59. [DOI: 10.1016/j.cld.2010.05.004] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 1.4] [Reference Citation Analysis]
32 Lee YB, Lee JH, Choi WM, Cho YY, Yoo JJ, Lee M, Lee DH, Cho Y, Yu SJ, Kim YJ. Efficacy of adefovir-based combination therapy for patients with Lamivudine- and entecavir-resistant chronic hepatitis B virus infection. Antimicrob Agents Chemother. 2013;57:6325-6332. [PMID: 24100506 DOI: 10.1128/aac.01742-13aac.01742-13] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
33 Gwak GY, Huh W, Lee DH, Choi MS, Lee JH, Koh KC, Kim SJ, Joh JW, Oh HY. The incidence and clinical outcome of YMDD mutants in hepatitis B surface antigen-positive renal allograft recipients after prolonged lamivudine therapy. Transplant Proc. 2007;39:3121-3126. [PMID: 18089336 DOI: 10.1016/j.transproceed.2007.06.081] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
34 Zoulim F, Locarnini S. Management of treatment failure in chronic hepatitis B. J Hepatol. 2012;56 Suppl 1:S112-S122. [PMID: 22300461 DOI: 10.1016/s0168-8278(12)60012-9] [Cited by in Crossref: 90] [Cited by in F6Publishing: 41] [Article Influence: 9.0] [Reference Citation Analysis]
35 Yoo BC, Kim JH, Kim TH, Koh KC, Um SH, Kim YS, Lee KS, Han BH, Chon CY, Han JY, Ryu SH, Kim HC, Byun KS, Hwang SG, Kim BI, Cho M, Yoo K, Lee HJ, Hwang JS, Kim YS, Lee YS, Choi SK, Lee YJ, Yang JM, Park JW, Lee MS, Kim DG, Chung YH, Cho SH, Choi JY, Kweon YO, Lee HY, Jeong SH, Yoo HW, Lee HS. Clevudine is highly efficacious in hepatitis B e antigen-negative chronic hepatitis B with durable off-therapy viral suppression. Hepatology 2007;46:1041-8. [PMID: 17647293 DOI: 10.1002/hep.21800] [Cited by in Crossref: 82] [Cited by in F6Publishing: 68] [Article Influence: 5.5] [Reference Citation Analysis]
36 Tenney DJ, Rose RE, Baldick CJ, Levine SM, Pokornowski KA, Walsh AW, Fang J, Yu CF, Zhang S, Mazzucco CE, Eggers B, Hsu M, Plym MJ, Poundstone P, Yang J, Colonno RJ. Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present. Antimicrob Agents Chemother 2007;51:902-11. [PMID: 17178796 DOI: 10.1128/AAC.00833-06] [Cited by in Crossref: 172] [Cited by in F6Publishing: 50] [Article Influence: 10.8] [Reference Citation Analysis]
37 Shen S, Jiang L, Xiao GQ, Yan LN, Yang JY, Wen TF, Li B, Wang WT, Xu MQ, Wei YG. Prophylaxis against hepatitis B virus recurrence after liver transplantation: A registry study. World J Gastroenterol 2015; 21(2): 584-592 [PMID: 25593480 DOI: 10.3748/wjg.v21.i2.584] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
38 Ghany M, Liang TJ. Drug Targets and Molecular Mechanisms of Drug Resistance in Chronic Hepatitis B. Gastroenterology 2007;132:1574-85. [DOI: 10.1053/j.gastro.2007.02.039] [Cited by in Crossref: 122] [Cited by in F6Publishing: 108] [Article Influence: 8.1] [Reference Citation Analysis]
39 Mauss S, Wedemeyer H. Treatment of chronic hepatitis B and the implications of viral resistance to therapy. Expert Review of Anti-infective Therapy 2014;6:191-9. [DOI: 10.1586/14787210.6.2.191] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
40 Devi U, Locarnini S. Hepatitis B antivirals and resistance. Current Opinion in Virology 2013;3:495-500. [DOI: 10.1016/j.coviro.2013.08.006] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
41 Lok AS. How to diagnose and treat hepatitis B virus antiviral drug resistance in the liver transplant setting. Liver Transpl. 2008;14 Suppl 2:S8-S14. [PMID: 18825720 DOI: 10.1002/lt.21616] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
42 Cuestas ML, Mathet VL, Oubiña JR, Sosnik A. Drug delivery systems and liver targeting for the improved pharmacotherapy of the hepatitis B virus (HBV) infection. Pharm Res 2010;27:1184-202. [PMID: 20333454 DOI: 10.1007/s11095-010-0112-z] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
43 Kuo A, Gish R. Chronic Hepatitis B Infection. Clinics in Liver Disease 2012;16:347-69. [DOI: 10.1016/j.cld.2012.03.003] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 3.2] [Reference Citation Analysis]
44 Chen EQ, Lei BJ, Tang H. Clinical application and research progress in hepatitis B virus quasispecies. Shijie Huaren Xiaohua Zazhi 2008; 16(10): 1086-1091 [DOI: 10.11569/wcjd.v16.i10.1086] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
45 Fukushima K, Ueno Y, Inoue J, Wakui Y, Obara N, Kimura O, Kido O, Nakagome Y, Kakazu E, Matsuda Y, Kogure T, Kondo Y, Nagasaki F, Yamagiwa Y, Ashino Y, Shimosegawa T. A case of HIV co-infected with hepatitis B virus precore/core deletion mutant treated by entecavir. Hepatol Res 2008;38:842-6. [PMID: 18498361 DOI: 10.1111/j.1872-034X.2008.00332.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
46 Kim DY, Chang HY, Lim SM, Kim SU, Park JY, Kim JK, Lee KS, Han KH, Chon CY, Ahn SH. Quasispecies and pre-existing drug-resistant mutations of hepatitis B virus in patients with chronic hepatitis B. Gut Liver 2013;7:329-34. [PMID: 23710315 DOI: 10.5009/gnl.2013.7.3.329] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
47 Liu B, Wen X, Huang C, Wei Y. Unraveling the complexity of hepatitis B virus: from molecular understanding to therapeutic strategy in 50 years. Int J Biochem Cell Biol 2013;45:1987-96. [PMID: 23819994 DOI: 10.1016/j.biocel.2013.06.017] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
48 Chang TT, Suh DJ. Current approaches for treating chronic hepatitis B: when to start, what to start with, and when to stop. Hepatol Int 2008;2:19-27. [PMID: 19669295 DOI: 10.1007/s12072-008-9059-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
49 Locarnini S. Primary resistance, multidrug resistance, and cross-resistance pathways in HBV as a consequence of treatment failure. Hepatol Int. 2008;2:147-151. [PMID: 19669299 DOI: 10.1007/s12072-008-9048-3] [Cited by in Crossref: 99] [Cited by in F6Publishing: 99] [Article Influence: 7.1] [Reference Citation Analysis]
50 Paganelli M, Stephenne X, Sokal EM. Chronic hepatitis B in children and adolescents. Journal of Hepatology 2012;57:885-96. [DOI: 10.1016/j.jhep.2012.03.036] [Cited by in Crossref: 52] [Cited by in F6Publishing: 44] [Article Influence: 5.2] [Reference Citation Analysis]
51 Ha NB, Ha NB, Trinh HN, Nguyen HA, Nguyen KK, Nguyen MH. Response to Higher Dose of Entecavir 1.0 mg Daily in Patients With Partial Response to Entecavir 0.5 mg Daily. Journal of Clinical Gastroenterology 2013;47:461-5. [DOI: 10.1097/mcg.0b013e318266fd31] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
52 Yildiz UH, Inci F, Wang S, Toy M, Tekin HC, Javaid A, Lau DT, Demirci U. Recent advances in micro/nanotechnologies for global control of hepatitis B infection. Biotechnol Adv 2015;33:178-90. [PMID: 25450190 DOI: 10.1016/j.biotechadv.2014.11.003] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 3.8] [Reference Citation Analysis]
53 Thai H, Campo DS, Lara J, Dimitrova Z, Ramachandran S, Xia G, Ganova-Raeva L, Teo CG, Lok A, Khudyakov Y. Convergence and coevolution of hepatitis B virus drug resistance. Nat Commun. 2012;3:789. [PMID: 22510694 DOI: 10.1038/ncomms1794] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 3.1] [Reference Citation Analysis]
54 Gwak G, Eo SJ, Shin SR, Choi MS, Lee JH, Koh KC, Paik SW, Yoo BC. A comparison of clevudine and entecavir for treatment-naïve patients with chronic hepatitis B: results after 2 years of treatment. Hepatol Int 2013;7:106-10. [DOI: 10.1007/s12072-012-9368-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
55 Leung N. Recent data on treatment of chronic hepatitis B with nucleos(t)ide analogues. Hepatol Int 2008;2:163-78. [PMID: 19669301 DOI: 10.1007/s12072-008-9061-6] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 1.9] [Reference Citation Analysis]
56 Potter M, Klein MB. Co-infections and co-therapies: treatment of HIV in the presence of hepatitis C and hepatitis B. HIV Therapy 2009;3:189-207. [DOI: 10.2217/17584310.3.2.189] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
57 Zheng J, Zeng Z, Zhang D, Yu Y, Wang F, Pan CQ. Prevalence and significance of Hepatitis B reverse transcriptase mutants in different disease stages of untreated patients. Liver Int. 2012;32:1535-1542. [PMID: 22882650 DOI: 10.1111/j.1478-3231.2012.02859.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
58 Yeh CT, Chen T, Hsu CW, Chen YC, Lai MW, Liang KH, Chen TC. Emergence of the rtA181T/sW172* mutant increased the risk of hepatoma occurrence in patients with lamivudine-resistant chronic hepatitis B. BMC Cancer. 2011;11:398. [PMID: 21933446 DOI: 10.1186/1471-2407-11-398] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 3.2] [Reference Citation Analysis]
59 Toy M, Hutton DW, So SK. Cost-Effectiveness and Cost Thresholds of Generic and Brand Drugs in a National Chronic Hepatitis B Treatment Program in China. PLoS One 2015;10:e0139876. [PMID: 26536626 DOI: 10.1371/journal.pone.0139876] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
60 Dan YY, Aung MO, Lim SG. The economics of treating chronic hepatitis B in Asia. Hepatol Int 2008;2:284-95. [PMID: 19669256 DOI: 10.1007/s12072-008-9049-2] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 1.6] [Reference Citation Analysis]
61 Li XG, Liu BM, Xu J, Liu XE, Ding H, Li T. Discrepancy of potential antiviral resistance mutation profiles within the HBV reverse transcriptase between nucleos(t)ide analogue-untreated and -treated patients with chronic hepatitis B in a hospital in China. J Med Virol. 2012;84:207-216. [PMID: 22170539 DOI: 10.1002/jmv.23182] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
62 Lee HW, Park JY, Ahn SH. An evaluation of entecavir for the treatment of chronic hepatitis B infection in adults. Expert Rev Gastroenterol Hepatol 2016;10:177-86. [PMID: 26610256 DOI: 10.1586/17474124.2016.1125781] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
63 Suzuki F, Akuta N, Suzuki Y, Yatsuji H, Sezaki H, Arase Y, Kawamura Y, Hosaka T, Kobayashi M, Ikeda K. Selection of a virus strain resistant to entecavir in a nucleoside-naive patient with hepatitis B of genotype H. J Clin Virol. 2007;39:149-152. [PMID: 17442615 DOI: 10.1016/j.jcv.2007.03.004] [Cited by in Crossref: 22] [Cited by in F6Publishing: 26] [Article Influence: 1.5] [Reference Citation Analysis]
64 Moriconi F, Colombatto P, Coco B, Ciccorossi P, Oliveri F, Flichman D, Maina AM, Sacco R, Bonino F, Brunetto MR. Emergence of hepatitis B virus quasispecies with lower susceptibility to nucleos(t)ide analogues during lamivudine treatment. J Antimicrob Chemother. 2007;60:341-349. [PMID: 17567633 DOI: 10.1093/jac/dkm187] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.0] [Reference Citation Analysis]
65 Wei C, Chong YT, Wen JZ, Li YW, Li G. Characterization of hepatitis virus B isolated from a multi-drug refractory patient. Virus Res 2011;155:254-8. [PMID: 20970466 DOI: 10.1016/j.virusres.2010.10.018] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
66 Lok AS, Zoulim F, Locarnini S, Bartholomeusz A, Ghany MG, Pawlotsky JM, Liaw YF, Mizokami M, Kuiken C;  Hepatitis B Virus Drug Resistance Working Group. Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology. 2007;46:254-265. [PMID: 17596850 DOI: 10.1002/hep.21698] [Cited by in Crossref: 328] [Cited by in F6Publishing: 306] [Article Influence: 21.9] [Reference Citation Analysis]
67 Langley DR, Walsh AW, Baldick CJ, Eggers BJ, Rose RE, Levine SM, Kapur AJ, Colonno RJ, Tenney DJ. Inhibition of hepatitis B virus polymerase by entecavir. J Virol. 2007;81:3992-4001. [PMID: 17267485 DOI: 10.1128/jvi.02395-06] [Cited by in Crossref: 125] [Cited by in F6Publishing: 60] [Article Influence: 8.3] [Reference Citation Analysis]
68 Kurashige N, Hiramatsu N, Ohkawa K, Oze T, Inoue Y, Kurokawa M, Yakushijin T, Igura T, Kiso S, Kanto T, Takehara T, Tamura S, Kasahara A, Oshita M, Hijioka T, Katayama K, Yoshihara H, Hayashi E, Imai Y, Kato M, Hayashi N. Initial viral response is the most powerful predictor of the emergence of YMDD mutant virus in chronic hepatitis B patients treated with lamivudine. Hepatology Research 2008;38:450-6. [DOI: 10.1111/j.1872-034x.2007.00292.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
69 Buster EH, Schalm SW, Janssen HL. Peginterferon for the treatment of chronic hepatitis B in the era of nucleos(t)ide analogues. Best Pract Res Clin Gastroenterol. 2008;22:1093-1108. [PMID: 19187869 DOI: 10.1016/j.bpg.2008.11.007] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
70 Liu L, Liu Y, Chen R, Li X, Luo D, Zhao Y, Li Q, Huang B, Wang FS, Liu X, Xu D. Prevalence of the entecavir-resistance-inducing mutation rtA186T in a large cohort of Chinese hepatitis B virus patients. Antiviral Res. 2019;164:131-138. [PMID: 30796932 DOI: 10.1016/j.antiviral.2019.02.012] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
71 Cox N, Tillmann H. Emerging pipeline drugs for hepatitis B infection. Expert Opin Emerg Drugs 2011;16:713-29. [PMID: 22195605 DOI: 10.1517/14728214.2011.646260] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
72 Cheng PN, Chang TT. Entecavir: a potent antiviral with minimal long-term resistance in nucleoside-naive chronic hepatitis B patients. Expert Rev Anti Infect Ther. 2008;6:569-579. [PMID: 18847396 DOI: 10.1586/14787210.6.5.569] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
73 Brunetto MR. Tailoring antiviral therapy in chronic hepatitis B patients with lamivudine resistance. Journal of Hepatology 2007;46:756-8. [DOI: 10.1016/j.jhep.2007.02.016] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
74 Su F, Dai J, Yang S, Jiang X, Cui X, Ning H, Li J, Huang M. Prevalence and types of drug-resistant variants in Chinese patients with acute hepatitis B. J Med Virol 2015;87:1527-31. [PMID: 26032700 DOI: 10.1002/jmv.24006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
75 Lu L, Yip B, Trinh H, Pan CQ, Han SH, Wong CC, Li J, Chan S, Krishnan G, Wong CC, Nguyen MH. Tenofovir-based alternate therapies for chronic hepatitis B patients with partial virological response to entecavir. J Viral Hepat 2015;22:675-81. [PMID: 25417914 DOI: 10.1111/jvh.12368] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
76 Ichai P, Samuel D. Management of Fulminant Hepatitis B. Curr Infect Dis Rep 2019;21:25. [PMID: 31165271 DOI: 10.1007/s11908-019-0682-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
77 Ma J, Zhang Y, Chen X, Jin Y, Chen D, Wu Y, Cui J, Wang H, Liu J, Li N, Gao F. Association of preexisting drug-resistance mutations and treatment failure in hepatitis B patients. PLoS One 2013;8:e67606. [PMID: 23935839 DOI: 10.1371/journal.pone.0067606] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
78 Osborn MK. Safety and efficacy of telbivudine for the treatment of chronic hepatitis B. Ther Clin Risk Manag 2009;5:789-98. [PMID: 19851526 DOI: 10.2147/tcrm.s5318] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
79 Rose RE, Hernandez D, Falk PJ, Ericson K, Zhou N, Thiry A, McPhee F. Discovery of the Novel Entecavir-Resistant Hepatitis B Virus Reverse Transcriptase A181C Substitution From an Integrated Genotypic Analysis. Hepatol Commun 2018;2:1123-35. [PMID: 30202825 DOI: 10.1002/hep4.1231] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
80 Yuen MF, Seto WK, Fung J, Wong DK, Yuen JC, Lai CL. Three years of continuous entecavir therapy in treatment-naïve chronic hepatitis B patients: VIRAL suppression, viral resistance, and clinical safety. Am J Gastroenterol. 2011;106:1264-1271. [PMID: 21364549 DOI: 10.1038/ajg.2011.45] [Cited by in Crossref: 108] [Cited by in F6Publishing: 103] [Article Influence: 9.8] [Reference Citation Analysis]
81 Oketani M, Ido A, Uto H, Tsubouchi H. Prevention of hepatitis B virus reactivation in patients receiving immunosuppressive therapy or chemotherapy: Prevention of HBV reactivation. Hepatology Research 2012;42:627-36. [DOI: 10.1111/j.1872-034x.2012.00998.x] [Cited by in Crossref: 55] [Cited by in F6Publishing: 25] [Article Influence: 5.5] [Reference Citation Analysis]
82 Carosi G, Rizzetto M. Treatment of chronic hepatitis B: recommendations from an Italian workshop. Dig Liver Dis. 2008;40:603-617. [PMID: 18499540 DOI: 10.1016/j.dld.2008.03.011] [Cited by in Crossref: 41] [Cited by in F6Publishing: 33] [Article Influence: 2.9] [Reference Citation Analysis]
83 Fang J, Wichroski MJ, Levine SM, Baldick CJ, Mazzucco CE, Walsh AW, Kienzle BK, Rose RE, Pokornowski KA, Colonno RJ, Tenney DJ. Ultrasensitive genotypic detection of antiviral resistance in hepatitis B virus clinical isolates. Antimicrob Agents Chemother 2009;53:2762-72. [PMID: 19433559 DOI: 10.1128/AAC.00130-09] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
84 Coffin CS, Fung SK, Alvarez F, Cooper CL, Doucette KE, Fournier C, Kelly E, Ko HH, Ma MM, Martin SR, Osiowy C, Ramji A, Tam E, Villeneuve JP. Management of Hepatitis B Virus Infection: 2018 Guidelines from the Canadian Association for the Study of Liver Disease and Association of Medical Microbiology and Infectious Disease Canada. CanLivJ 2018;1:156-217. [DOI: 10.3138/canlivj.2018-0008] [Cited by in Crossref: 23] [Cited by in F6Publishing: 7] [Article Influence: 5.8] [Reference Citation Analysis]
85 Yan Y, Mai L, Zheng YB, Zhang SQ, Xu WX, Gao ZL, Ke WM. What MELD score mandates use of entecavir for ACLF-HBV HBeAg-negative patients? World J Gastroenterol 2012; 18(33): 4604-4609 [PMID: 22969236 DOI: 10.3748/wjg.v18.i33.4604] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
86 Zarski JP, Leroy V. [The patient with uncontrolled chronic hepatitis B]. Gastroenterol Clin Biol 2008;32:S7-11. [PMID: 18662613 DOI: 10.1016/S0399-8320(08)73259-7] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
87 Teppa E, Nadalin F, Combet C, Zea DJ, David L, Carbone A. Coevolution analysis of amino-acids reveals diversified drug-resistance solutions in viral sequences: a case study of hepatitis B virus. Virus Evol 2020;6:veaa006. [PMID: 32158552 DOI: 10.1093/ve/veaa006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
88 Chang TT. On-treatment monitoring of HBV DNA levels: predicting response and resistance to oral antiviral therapy at week 24 versus week 48. Hepatol Int 2009;3 Suppl 1:16-23. [PMID: 19669242 DOI: 10.1007/s12072-009-9143-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
89 Marino A, Cosentino F, Ceccarelli M, Moscatt V, Pampaloni A, Scuderi D, D'Andrea F, Rullo EV, Nunnari G, Benanti F, Celesia BM, Cacopardo B. Entecavir resistance in a patient with treatment-naïve HBV: A case report. Mol Clin Oncol 2021;14:113. [PMID: 33903819 DOI: 10.3892/mco.2021.2275] [Reference Citation Analysis]
90 Yurdaydin C. Entecavir: a step forward in combating hepatitis B disease. Expert Opinion on Pharmacotherapy 2008;9:3095-109. [DOI: 10.1517/14656560802515546] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
91 Hagiwara S, Kudo M, Osaki Y, Matsuo H, Inuzuka T, Matsumoto A, Tanaka E, Sakurai T, Ueshima K, Inoue T. Impact of peginterferon alpha-2b and entecavir hydrate combination therapy on persistent viral suppression in patients with chronic hepatitis B. J Med Virol. 2013;85:987-995. [PMID: 23588724 DOI: 10.1002/jmv.23564] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
92 Giang L, Selinger CP, Lee AU. Evaluation of adherence to oral antiviral hepatitis B treatment using structured questionnaires. World J Hepatol 2012; 4(2): 43-49 [PMID: 22400085 DOI: 10.4254/wjh.v4.i2.43] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
93 Chung GE, Kim W, Lee KL, Hwang SY, Lee JH, Kim HY, Jung YJ, Kim D, Jeong JB, Kim BG. Add-on adefovir is superior to a switch to entecavir as rescue therapy for Lamivudine-resistant chronic hepatitis B. Dig Dis Sci. 2011;56:2130-2136. [PMID: 21253834 DOI: 10.1007/s10620-010-1561-2] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.4] [Reference Citation Analysis]
94 Karino Y, Toyota J, Kumada H, Katano Y, Izumi N, Kobashi H, Sata M, Moriyama M, Imazeki F, Kage M. Efficacy and resistance of entecavir following 3 years of treatment of Japanese patients with lamivudine-refractory chronic hepatitis B. Hepatol Int. 2010;4:414-422. [PMID: 20305760 DOI: 10.1007/s12072-009-9162-x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.4] [Reference Citation Analysis]
95 Cai Y, Wang N, Wu X, Zheng K, Li Y. Compensatory variances of drug-induced hepatitis B virus YMDD mutations. Springerplus 2016;5:1340. [PMID: 27588233 DOI: 10.1186/s40064-016-3003-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
96 Zoulim F, Buti M, Lok AS. Antiviral-resistant hepatitis B virus: can we prevent this monster from growing? J Viral Hepat. 2007;14 Suppl 1:29-36. [PMID: 17958640 DOI: 10.1111/j.1365-2893.2007.00915.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 2.5] [Reference Citation Analysis]
97 Xu X, Xiang K, Su M, Li Y, Ji W, Li Y, Zhuang H, Li T. HBV Drug Resistance Substitutions Existed before the Clinical Approval of Nucleos(t)ide Analogues: A Bioinformatic Analysis by GenBank Data Mining. Viruses 2017;9:E199. [PMID: 28749433 DOI: 10.3390/v9080199] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
98 Chakravarty R. Role of molecular diagnostics in the management of viral hepatitis B. Expert Opin Med Diagn 2012;6:395-406. [PMID: 23480805 DOI: 10.1517/17530059.2012.690391] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
99 Sánchez-tapias JM. Fármacos para el tratamiento de la hepatitis B crónica. Gastroenterología y Hepatología 2008;31:120-8. [DOI: 10.1157/13116500] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
100 Dusheiko G. Treatment of HBeAg positive chronic hepatitis B: interferon or nucleoside analogues. Liver Int. 2013;33 Suppl 1:137-150. [PMID: 23286858 DOI: 10.1111/liv.12078] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 3.2] [Reference Citation Analysis]
101 Karatayli E, Karatayli SC, Cinar K, Gokahmetoglu S, Güven K, Idilman R, Yurdaydin C, Bozdayi AM. Molecular characterization of a novel entecavir mutation pattern isolated from a multi-drug refractory patient with chronic hepatitis B infection. J Clin Virol. 2012;53:130-134. [PMID: 22078148 DOI: 10.1016/j.jcv.2011.10.011] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
102 Ha NB, Ha NB, Chaung KT, Trinh HN, Nguyen HA, Nguyen KK, Nguyen MH. Similar Response to Entecavir 0.5 and 1.0 Mg in Treatment-Naïve Chronic Hepatitis B Patients: A Case-Control Study. Dig Dis Sci 2014;59:168-73. [DOI: 10.1007/s10620-013-2940-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
103 Valsamakis A. Molecular testing in the diagnosis and management of chronic hepatitis B. Clin Microbiol Rev. 2007;20:426-439, table of contents. [PMID: 17630333 DOI: 10.1128/cmr.00009-07] [Cited by in Crossref: 86] [Cited by in F6Publishing: 32] [Article Influence: 5.7] [Reference Citation Analysis]
104 Suzuki F, Akuta N, Suzuki Y, Yatsuji H, Sezaki H, Arase Y, Hirakawa M, Kawamura Y, Hosaka T, Kobayashi M. Efficacy of switching to entecavir monotherapy in Japanese lamivudine-pretreated patients. J Gastroenterol Hepatol. 2010;25:892-898. [PMID: 20546442 DOI: 10.1111/j.1440-1746.2009.06161.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
105 Papatheodoridis GV, Manolakopoulos S, Dusheiko G, Archimandritis AJ. Therapeutic strategies in the management of patients with chronic hepatitis B virus infection. Lancet Infect Dis. 2008;8:167-178. [PMID: 18053766 DOI: 10.1016/s1473-3099(07)70264-5] [Cited by in Crossref: 138] [Cited by in F6Publishing: 55] [Article Influence: 9.2] [Reference Citation Analysis]
106 Marugán RB, Garzón SG. DNA-guided hepatitis B treatment, viral load is essential, but not sufficient. World J Gastroenterol 2009; 15(4): 423-430 [PMID: 19152446 DOI: 10.3748/wjg.15.423] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 18] [Article Influence: 1.1] [Reference Citation Analysis]
107 Zhu Y, Curtis M, Snow-Lampart A, Yang H, Delaney W, Miller MD, Borroto-Esoda K. In vitro drug susceptibility analysis of hepatitis B virus clinical quasispecies populations. J Clin Microbiol. 2007;45:3335-3341. [PMID: 17687019 DOI: 10.1128/JCM.00272-07] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
108 Mao R, Yin Y, Qin Y, Wu X, Weng X, Zhang J, Lu M. Spontaneous HBeAg seroconversion and loss of hepatitis B virus DNA after acute flare due to development of drug resistant mutants during entecavir monotherapy. Hepatology Research 2009;39:14-20. [DOI: 10.1111/j.1872-034x.2008.00411.x] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
109 Di Marco V, Craxì A. Chronic hepatitis B: who to treat and which choice of treatment? Expert Rev Anti Infect Ther 2009;7:281-91. [PMID: 19344242 DOI: 10.1586/eri.09.4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
110 Nguyen MH, Garcia RT, Trinh HN, Nguyen HA, Nguyen KK, Nguyen LH, Levitt B. Prevalence of hepatitis B virus DNA polymerase mutations in treatment-naïve patients with chronic hepatitis B. Aliment Pharmacol Ther 2009;30:1150-8. [PMID: 19785624 DOI: 10.1111/j.1365-2036.2009.04151.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.2] [Reference Citation Analysis]
111 Hu JL, Cui J, Guo JJ, Zhang WL, Cai XF, Yuan ZW, Li QL, Deng XY, Zeng AZ, Hu Y, Tang N, Huang AL. Phenotypic assay of a hepatitis B virus strain carrying an rtS246T variant using a new strategy. J Med Virol 2012;84:34-43. [PMID: 22052677 DOI: 10.1002/jmv.22260] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
112 Carey I, Harrison PM. Monotherapy versus combination therapy for the treatment of chronic hepatitis B. Expert Opin Investig Drugs. 2009;18:1655-1666. [PMID: 19852566 DOI: 10.1517/13543780903241599] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 2.3] [Reference Citation Analysis]
113 Kayaaslan B, Akinci E, Ari A, Tufan ZK, Alpat SN, Gunal O, Tosun S, Guner R, Tabak F. A long-term multicenter study: Entecavir versus Tenofovir in treatment of nucleos(t)ide analogue-naive chronic hepatitis B patients. Clin Res Hepatol Gastroenterol 2018;42:40-7. [PMID: 28757048 DOI: 10.1016/j.clinre.2017.06.008] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
114 Almeida AM, Ribeiro AQ, Pádua CA, Brandão CM, Andrade EI, Cherchiglia ML, Carmo RA, Acurcio Fde A. [The efficacy of adefovir dipivoxil, entecavir and telbivudine for chronic hepatitis B treatment: a systematic review]. Rev Soc Bras Med Trop 2010;43:440-51. [PMID: 20802947 DOI: 10.1590/s0037-86822010000400021] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
115 Feld JJ, Colledge D, Sozzi V, Edwards R, Littlejohn M, Locarnini SA. The phenylpropenamide derivative AT-130 blocks HBV replication at the level of viral RNA packaging. Antiviral Res 2007;76:168-77. [PMID: 17709147 DOI: 10.1016/j.antiviral.2007.06.014] [Cited by in Crossref: 118] [Cited by in F6Publishing: 105] [Article Influence: 7.9] [Reference Citation Analysis]
116 Yatsuji H, Suzuki F, Sezaki H, Akuta N, Suzuki Y, Kawamura Y, Hosaka T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Watahiki S, Iwasaki S, Kobayashi M, Kumada H. Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: Two-year follow-up. Journal of Hepatology 2008;48:923-31. [DOI: 10.1016/j.jhep.2008.02.019] [Cited by in Crossref: 79] [Cited by in F6Publishing: 68] [Article Influence: 5.6] [Reference Citation Analysis]
117 Veenstra DL, Spackman DE, Bisceglie A, Kowdley KV, Gish RG. Evaluating anti-viral drug selection and treatment duration in HBeAg-negative chronic hepatitis B: a cost-effectiveness analysis: EVALUATING ANTI-VIRAL THERAPY IN HBEAG-NEGATIVE CHB. Alimentary Pharmacology & Therapeutics 2008;27:1240-52. [DOI: 10.1111/j.1365-2036.2008.03691.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 1.6] [Reference Citation Analysis]
118 Toy M, Onder FO, Idilman R, Kabacam G, Richardus JH, Bozdayi M, Akdogan M, Kuloglu Z, Kansu A, Schalm S, Yurdaydin C. The cost-effectiveness of treating chronic hepatitis B patients in a median endemic and middle income country. Eur J Health Econ 2012;13:663-76. [PMID: 22815098 DOI: 10.1007/s10198-012-0413-8] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
119 Sulkowski MS. Management of hepatic complications in HIV-infected persons. J Infect Dis 2008;197 Suppl 3:S279-93. [PMID: 18447614 DOI: 10.1086/533414] [Cited by in Crossref: 51] [Cited by in F6Publishing: 53] [Article Influence: 3.6] [Reference Citation Analysis]
120 Hayashi S, Murakami S, Omagari K, Matsui T, Iio E, Isogawa M, Watanabe T, Karino Y, Tanaka Y. Characterization of novel entecavir resistance mutations. J Hepatol. 2015;63:546-553. [PMID: 25817219 DOI: 10.1016/j.jhep.2015.03.020] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 5.4] [Reference Citation Analysis]
121 Dougherty AM, Guo H, Westby G, Liu Y, Simsek E, Guo JT, Mehta A, Norton P, Gu B, Block T, Cuconati A. A substituted tetrahydro-tetrazolo-pyrimidine is a specific and novel inhibitor of hepatitis B virus surface antigen secretion. Antimicrob Agents Chemother 2007;51:4427-37. [PMID: 17875990 DOI: 10.1128/AAC.00541-07] [Cited by in Crossref: 69] [Cited by in F6Publishing: 22] [Article Influence: 4.6] [Reference Citation Analysis]
122 Singla B, Bhattacharyya R, Chakraborti A, Sharma BK, Kapil S, Chawla YK, Arora SK, Das A, Dhiman RK, Duseja A. Response to potent anti-HBV agents in chronic hepatitis B and combined effect of HBV reverse transcriptase mutations. Gene 2015;567:22-30. [PMID: 25917965 DOI: 10.1016/j.gene.2015.04.060] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
123 Xi ZF, Xia Q. Recent advances in prevention of hepatitis B recurrence after liver transplantation. World J Gastroenterol 2015; 21(3): 829-835 [PMID: 25624716 DOI: 10.3748/wjg.v21.i3.829] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
124 Zoulim F, Perrillo R. Hepatitis B: reflections on the current approach to antiviral therapy. J Hepatol. 2008;48 Suppl 1:S2-S19. [PMID: 18304680 DOI: 10.1016/j.jhep.2008.01.011] [Cited by in Crossref: 107] [Cited by in F6Publishing: 106] [Article Influence: 7.6] [Reference Citation Analysis]
125 Matsuura K, Tanaka Y, Kusakabe A, Hige S, Inoue J, Komatsu M, Kuramitsu T, Hirano K, Ohno T, Hasegawa I, Kobashi H, Hino K, Hiasa Y, Nomura H, Sugauchi F, Nojiri S, Joh T, Mizokami M. Recommendation of lamivudine-to-entecavir switching treatment in chronic hepatitis B responders: Randomized controlled trial: LAM-to-ETV switching treatment. Hepatology Research 2011;41:505-11. [DOI: 10.1111/j.1872-034x.2011.00807.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
126 Fu Y, Zeng Y, Chen T, Chen H, Lin N, Lin J, Liu X, Huang E, Wu S, Wu S, Xu S, Wang L, Ou Q. Characterization and Clinical Significance of Natural Variability in Hepatitis B Virus Reverse Transcriptase in Treatment-Naive Chinese Patients by Sanger Sequencing and Next-Generation Sequencing. J Clin Microbiol 2019;57:e00119-19. [PMID: 31189581 DOI: 10.1128/JCM.00119-19] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
127 Brunetto MR, Colombatto P, Bonino F. Personalized therapy in chronic viral hepatitis. Mol Aspects Med 2008;29:103-11. [PMID: 18068759 DOI: 10.1016/j.mam.2007.09.015] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
128 Ozaras R, Leblebicioglu H. How to compare antivirals in the treatment of chronic hepatitis B? Ann Clin Microbiol Antimicrob 2009;8:6. [PMID: 19254373 DOI: 10.1186/1476-0711-8-6] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
129 Shouval D, Lai CL, Chang TT, Cheinquer H, Martin P, Carosi G, Han S, Kaymakoglu S, Tamez R, Yang J. Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: the case for continuous antiviral therapy. J Hepatol. 2009;50:289-295. [PMID: 19070393 DOI: 10.1016/j.jhep.2008.10.017] [Cited by in Crossref: 75] [Cited by in F6Publishing: 76] [Article Influence: 5.4] [Reference Citation Analysis]
130 Lopez-Suñé E, Tuset M, Laguno M, Moreno A, Miró JM. [Characteristics of hepatitis and influenza antivirals: update 2009]. Enferm Infecc Microbiol Clin 2010;28:253.e1-17. [PMID: 20395018 DOI: 10.1016/j.eimc.2010.02.001] [Reference Citation Analysis]
131 Erstad DJ, Razavi AA, Li S, Tanabe KK, Fuchs BC. Prevention Strategies for Hepatocellular Carcinoma. In: Hoshida Y, editor. Hepatocellular Carcinoma. Cham: Springer International Publishing; 2019. pp. 255-89. [DOI: 10.1007/978-3-030-21540-8_13] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
132 Ohishi W, Chayama K. Treatment of chronic hepatitis B with nucleos(t)ide analogues. Hepatol Res. 2012;42:219-225. [PMID: 22176139 DOI: 10.1111/j.1872-034x.2011.00921.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
133 Batirel A, Guclu E, Arslan F, Kocak F, Karabay O, Ozer S, Turanli M, Mert A. Comparable efficacy of tenofovir versus entecavir and predictors of response in treatment-naïve patients with chronic hepatitis B: a multicenter real-life study. Int J Infect Dis 2014;28:153-9. [PMID: 25286184 DOI: 10.1016/j.ijid.2014.09.004] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 3.3] [Reference Citation Analysis]
134 Bailly F, Zoulim F. [Treatment of hepatitis B. Therapeutic management]. Gastroenterol Clin Biol 2008;32:S172-8. [PMID: 18472238 DOI: 10.1016/j.gcb.2008.04.008] [Reference Citation Analysis]
135 Jardi R, Rodriguez-Frias F, Schaper M, Ruiz G, Elefsiniotis I, Esteban R, Buti M. Hepatitis B virus polymerase variants associated with entecavir drug resistance in treatment-naive patients. J Viral Hepat. 2007;14:835-840. [PMID: 18070286 DOI: 10.1111/j.1365-2893.2007.00877.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 13] [Article Influence: 0.2] [Reference Citation Analysis]
136 Qiu J, Xu B, Huang Z, Pan W, Cao P, Liu C, Hao X, Song B, Liang G. Synthesis and biological evaluation of Matijing-Su derivatives as potent anti-HBV agents. Bioorganic & Medicinal Chemistry 2011;19:5352-60. [DOI: 10.1016/j.bmc.2011.08.001] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 2.8] [Reference Citation Analysis]
137 Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology. 2007;45:507-539. [PMID: 17256718 DOI: 10.1002/hep.21513] [Cited by in Crossref: 1675] [Cited by in F6Publishing: 1543] [Article Influence: 111.7] [Reference Citation Analysis]
138 Shindo M, Chayama K, Mochida S, Toyota J, Tomita E, Kumada H, Yokosuka O, Sata M, Hayashi N, Suzuki K, Okanoue T, Tsubouchi H, Ishikawa H, Seriu T, Omata M. Antiviral activity, dose-response relationship, and safety of entecavir following 24-week oral dosing in nucleoside-naive Japanese adult patients with chronic hepatitis B: a randomized, double-blind, phase II clinical trial. Hepatol Int 2009;3:445-52. [PMID: 19669249 DOI: 10.1007/s12072-009-9135-0] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
139 Kim JD, Choi JY, Bae SH, Yoon SK, Yang JM, Han NI, Choi SW, Lee CD, Lee YS, Jung ES. Hepatitis B Virus Load in Serum Does Not Reflect Histologic Activity in Patients With Decompensated Cirrhosis. Clinical Gastroenterology and Hepatology 2010;8:60-5. [DOI: 10.1016/j.cgh.2009.09.026] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
140 Lee JH, Cho Y, Lee DH, Lee M, Yoo JJ, Choi WM, Cho YY, Lee YB, Yu SJ, Yoon JH. Prior exposure to lamivudine increases entecavir resistance risk in chronic hepatitis B Patients without detectable lamivudine resistance. Antimicrob Agents Chemother. 2014;58:1730-1737. [PMID: 24395227 DOI: 10.1128/aac.02483-13] [Cited by in Crossref: 23] [Cited by in F6Publishing: 14] [Article Influence: 2.9] [Reference Citation Analysis]
141 Degertekin B, Lok AS. Monitoring antiviral resistance in patients receiving nucleos(t)ide analog therapies for hepatitis B: Which method should be used? Journal of Hepatology 2008;48:892-4. [DOI: 10.1016/j.jhep.2008.03.010] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
142 Yatsuji H, Hiraga N, Mori N, Hatakeyama T, Tsuge M, Imamura M, Takahashi S, Fujimoto Y, Ochi H, Abe H. Successful treatment of an entecavir-resistant hepatitis B virus variant. J Med Virol. 2007;79:1811-1817. [PMID: 17935165 DOI: 10.1002/jmv.20981] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 1.6] [Reference Citation Analysis]
143 Liu Y, Ho WI, Deng F, Peng S, Lau WY, Chen H. Entecavir Monotherapy Prevents Hepatitis B Virus Recurrence After Liver Transplant for Chronic Hepatitis B Patients: A Long-Term Retrospective Study. Transplant Proc 2021;53:1700-6. [PMID: 34030872 DOI: 10.1016/j.transproceed.2021.04.007] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
144 Tenney DJ, Rose RE, Baldick CJ, Pokornowski KA, Eggers BJ, Fang J, Wichroski MJ, Xu D, Yang J, Wilber RB, Colonno RJ. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy. Hepatology 2009;49:1503-14. [DOI: 10.1002/hep.22841] [Cited by in Crossref: 564] [Cited by in F6Publishing: 524] [Article Influence: 43.4] [Reference Citation Analysis]
145 Liu C, Ye J, Jia H, Zhang M, Han H, Chen F, Chen C. Entecavir and lamivudine therapy for severe acute chronic hepatitis B. Exp Ther Med. 2013;5:545-548. [PMID: 23403957 DOI: 10.3892/etm.2012.850] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
146 Holness G, Carriero DC, Dieterich DT. Hepatitis B therapies and antiviral resistance detection and management. Expert Review of Gastroenterology & Hepatology 2014;3:693-9. [DOI: 10.1586/egh.09.64] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
147 Ismail AM, Samuel P, Eapen CE, Kannangai R, Abraham P. Antiviral resistance mutations and genotype-associated amino acid substitutions in treatment-naïve hepatitis B virus-infected individuals from the Indian subcontinent. Intervirology 2012;55:36-44. [PMID: 21311172 DOI: 10.1159/000323521] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 2.2] [Reference Citation Analysis]
148 Yao G, Chen C, Lu W, Ren H, Tan D, Wang Y, Xu D, Liu J, Xu D, Llamoso C. Virologic, serologic, and biochemical outcomes through 2 years of treatment with entecavir and lamivudine in nucleoside-naïve Chinese patients with chronic hepatitis B: a randomized, multicenter study. Hepatol Int. 2008;2:486-493. [PMID: 19669324 DOI: 10.1007/s12072-008-9088-8] [Cited by in Crossref: 15] [Cited by in F6Publishing: 21] [Article Influence: 1.1] [Reference Citation Analysis]
149 Tong J, Li QL, Huang AL, Guo JJ. Complexity and diversity of hepatitis B virus quasispecies: correlation with long-term entecavir antiviral efficacy. Antiviral Res. 2013;99:312-317. [PMID: 23832087 DOI: 10.1016/j.antiviral.2013.06.020] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
150 Gao S, Duan ZP, Coffin CS. Clinical relevance of hepatitis B virus variants. World J Hepatol 2015; 7(8): 1086-1096 [PMID: 26052397 DOI: 10.4254/wjh.v7.i8.1086] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 4.1] [Reference Citation Analysis]
151 Solmone M, Vincenti D, Prosperi MC, Bruselles A, Ippolito G, Capobianchi MR. Use of massively parallel ultradeep pyrosequencing to characterize the genetic diversity of hepatitis B virus in drug-resistant and drug-naive patients and to detect minor variants in reverse transcriptase and hepatitis B S antigen. J Virol. 2009;83:1718-1726. [PMID: 19073746 DOI: 10.1128/jvi.02011-08] [Cited by in Crossref: 126] [Cited by in F6Publishing: 79] [Article Influence: 9.0] [Reference Citation Analysis]
152 Drafting Committee for Hepatitis Management Guidelines and the Japan Society of Hepatology. JSH Guidelines for the Management of Hepatitis B Virus Infection. Hepatol Res. 2014;44 Suppl S1:1-58. [PMID: 24397839 DOI: 10.1111/hepr.12269] [Cited by in Crossref: 103] [Cited by in F6Publishing: 103] [Article Influence: 12.9] [Reference Citation Analysis]
153 Lee TC, Eckman MH, Shah SA. Cost-Effectiveness of Utilization of Hepatitis B Virus-Positive Liver Donors for HBV-Negative Transplant Recipients. J Gastrointest Surg 2021;25:1760-9. [DOI: 10.1007/s11605-020-04759-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
154 Rodriguez-Frias F, Buti M, Tabernero D, Homs M. Quasispecies structure, cornerstone of hepatitis B virus infection: Mass sequencing approach. World J Gastroenterol 2013; 19(41): 6995-7023 [PMID: 24222943 DOI: 10.3748/wjg.v19.i41.6995] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 28] [Article Influence: 3.2] [Reference Citation Analysis]
155 Lau G, Marcellin P, Peters M. Chronic hepatitis B: a global health problem requiring coherent worldwide treatment strategies. Hepatol Int 2007;1:316-25. [PMID: 19669356 DOI: 10.1007/s12072-007-9006-5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
156 Lau DT, Bleibel W. Current status of antiviral therapy for hepatitis B. Therap Adv Gastroenterol. 2008;1:61-75. [PMID: 21180515 DOI: 10.1177/1756283x08093944] [Cited by in Crossref: 17] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
157 Zhu Y, Curtis M, Qi X, Miller MD, Borroto-Esoda K. Anti-hepatitis B virus activity in vitro of combinations of tenofovir with nucleoside/nucleotide analogues. Antivir Chem Chemother 2009;19:165-76. [PMID: 19374144 DOI: 10.1177/095632020901900404] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
158 Kohrt HE, Ouyang DL, Keeffe EB. Antiviral prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection. Clin Liver Dis. 2007;11:965-991. [PMID: 17981237 DOI: 10.1016/j.cld.2007.08.006] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 2.8] [Reference Citation Analysis]
159 Kobashi H, Fujioka S, Kawaguchi M, Kumada H, Yokosuka O, Hayashi N, Suzuki K, Okanoue T, Sata M, Tsubouchi H, Sato C, Kiyosawa K, Tanikawa K, Seriu T, Ishikawa H, Takaki A, Iwasaki Y, Osawa T, Takaki T, Sakaguchi K, Shiratori Y, Yamamoto K, Tenney DJ, Omata M. Two cases of development of entecavir resistance during entecavir treatment for nucleoside-naive chronic hepatitis B. Hepatol Int 2009;3:403-10. [PMID: 19669367 DOI: 10.1007/s12072-008-9108-8] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
160 Iser DM, Sasadeusz JJ. Current treatment of HIV/hepatitis B virus coinfection. J Gastroenterol Hepatol 2008;23:699-706. [PMID: 18410604 DOI: 10.1111/j.1440-1746.2008.05382.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
161 Dezhbord M, Lee S, Kim W, Seong BL, Ryu WS. Characterization of the molecular events of covalently closed circular DNA synthesis in de novo Hepatitis B virus infection of human hepatoma cells. Antiviral Res 2019;163:11-8. [PMID: 30639437 DOI: 10.1016/j.antiviral.2019.01.004] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
162 Watanabe M, Shibuya A, Takada J, Tanaka Y, Okuwaki Y, Minamino T, Hidaka H, Nakazawa T, Koizumi W. Entecavir is an optional agent to prevent hepatitis B virus (HBV) reactivation: a review of 16 patients. Eur J Intern Med. 2010;21:333-337. [PMID: 20603047 DOI: 10.1016/j.ejim.2010.04.010] [Cited by in Crossref: 21] [Cited by in F6Publishing: 27] [Article Influence: 1.8] [Reference Citation Analysis]
163 Tchesnokov EP, Obikhod A, Schinazi RF, Götte M. Delayed chain termination protects the anti-hepatitis B virus drug entecavir from excision by HIV-1 reverse transcriptase. J Biol Chem 2008;283:34218-28. [PMID: 18940786 DOI: 10.1074/jbc.M806797200] [Cited by in Crossref: 44] [Cited by in F6Publishing: 36] [Article Influence: 3.1] [Reference Citation Analysis]
164 Su QM, Ye XG. Effects of telbivudine and entecavir for HBeAg-positive chronic hepatitis B: A meta-analysis. World J Gastroenterol 2012; 18(43): 6290-6301 [PMID: 23180951 DOI: 10.3748/wjg.v18.i43.6290] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
165 Cho SW, Koh KH, Cheong JY, Lee MH, Hong SP, Yoo WD, Kim S. Low efficacy of entecavir therapy in adefovir-refractory hepatitis B patients with prior lamivudine resistance. Journal of Viral Hepatitis 2010;17:171-7. [DOI: 10.1111/j.1365-2893.2009.01161.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
166 Kobashi H, Takaguchi K, Ikeda H, Yokosuka O, Moriyama M, Imazeki F, Kage M, Seriu T, Omata M, Sakaguchi K, Shiratori Y. Efficacy and safety of entecavir in nucleoside-naive, chronic hepatitis B patients: Phase II clinical study in Japan. Journal of Gastroenterology and Hepatology 2009;24:255-61. [DOI: 10.1111/j.1440-1746.2008.05593.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
167 Harigai M, Mochida S, Mimura T, Koike T, Miyasaka N. A proposal for management of rheumatic disease patients with hepatitis B virus infection receiving immunosuppressive therapy. Mod Rheumatol. 2014;24:1-7. [PMID: 24261752 DOI: 10.3109/14397595.2013.852834] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
168 Kimberlin DW. Antiviral Agents. Principles and Practice of Pediatric Infectious Diseases. Elsevier; 2018. pp. 1551-1567.e6. [DOI: 10.1016/b978-0-323-40181-4.00295-4] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
169 Chang TT, Lai CL, Kew Yoon S, Lee SS, Coelho HS, Carrilho FJ, Poordad F, Halota W, Horsmans Y, Tsai N, Zhang H, Tenney DJ, Tamez R, Iloeje U. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology. 2010;51:422-430. [PMID: 20049753 DOI: 10.1002/hep.23327] [Cited by in Crossref: 397] [Cited by in F6Publishing: 376] [Article Influence: 33.1] [Reference Citation Analysis]
170 Zhang Q, Jiang Z, Luo J, Ma Y, Liu J, Guo R, Zhang X, Zhou J, Niu W, Du F, Li L, Li C, Chen J. Anti-HBV agents. Part 3: Preliminary structure–activity relationships of tetra-acylalisol A derivatives as potent hepatitis B virus inhibitors. Bioorganic & Medicinal Chemistry Letters 2009;19:6659-65. [DOI: 10.1016/j.bmcl.2009.10.006] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
171 Pan CQ, Tong M, Kowdley KV, Hu K, Chang T, Lai C, Yoon SK, Lee SS, Cohen D, Tang H, Tsai N. High Rates of Viral Suppression After Long-term Entecavir Treatment of Asian Patients With Hepatitis B e Antigen–Positive Chronic Hepatitis B. Clinical Gastroenterology and Hepatology 2012;10:1047-1050.e1. [DOI: 10.1016/j.cgh.2012.03.016] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
172 Ishikawa T. Anti-viral therapy to reduce recurrence and improve survival in hepatitis B virus-related hepatocellular carcinoma. World J Gastroenterol 2013; 19(47): 8861-8866 [PMID: 24379608 DOI: 10.3748/wjg.v19.i47.8861] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
173 Zoulim F, Locarnini S. Optimal management of chronic hepatitis B patients with treatment failure and antiviral drug resistance. Liver Int 2013;33:116-24. [DOI: 10.1111/liv.12069] [Cited by in Crossref: 48] [Cited by in F6Publishing: 49] [Article Influence: 5.3] [Reference Citation Analysis]
174 Inada M, Yokosuka O. Current antiviral therapies for chronic hepatitis B. Hepatol Res. 2008;38:535-542. [PMID: 18452480 DOI: 10.1111/j.1872-034X.2008.00323.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
175 Sherman M, Yurdaydin C, Simsek H, Silva M, Liaw YF, Rustgi VK, Sette H, Tsai N, Tenney DJ, Vaughan J. Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks. Hepatology. 2008;48:99-108. [PMID: 18537189 DOI: 10.1002/hep.22323] [Cited by in Crossref: 122] [Cited by in F6Publishing: 110] [Article Influence: 8.7] [Reference Citation Analysis]
176 Hynicka LM, Yunker N, Patel PH. A Review of Oral Antiretroviral Therapy for the Treatment of Chronic Hepatitis B. Ann Pharmacother 2010;44:1271-86. [DOI: 10.1345/aph.1m590] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
177 Coffin CS, Fung SK, Ma MM; Canadian Association for the Study of the Liver. Management of chronic hepatitis B: Canadian Association for the Study of the Liver consensus guidelines. Can J Gastroenterol 2012;26:917-38. [PMID: 23248795 DOI: 10.1155/2012/506819] [Cited by in Crossref: 38] [Cited by in F6Publishing: 41] [Article Influence: 4.2] [Reference Citation Analysis]
178 Yap DY, Tang CS, Yung S, Choy BY, Yuen MF, Chan TM. Long-term outcome of renal transplant recipients with chronic hepatitis B infection-impact of antiviral treatments. Transplantation. 2010;90:325-330. [PMID: 20562676 DOI: 10.1097/tp.0b013e3181e5b811] [Cited by in Crossref: 45] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
179 Gao L, Trinh HN, Li J, Nguyen MH. Tenofovir is superior to entecavir for achieving complete viral suppression in HBeAg-positive chronic hepatitis B patients with high HBV DNA. Aliment Pharmacol Ther 2014;39:629-37. [PMID: 24467455 DOI: 10.1111/apt.12629] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 2.9] [Reference Citation Analysis]
180 Beckebaum S, Sotiropoulos GC, Gerken G, Cicinnati VR. Hepatitis B and liver transplantation: 2008 update. Rev Med Virol 2009;19:7-29. [DOI: 10.1002/rmv.595] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
181 Matsue K, Aoki T, Odawara J, Fujiwara H, Iwama K, Kimura S, Yamakura M, Takeuch M. High risk of hepatitis B-virus reactivation after hematopoietic cell transplantation in hepatitis B core antibody-positive patients. Eur J Haematol 2009;83:357-64. [PMID: 19508685 DOI: 10.1111/j.1600-0609.2009.01291.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
182 Cathcart AL, Chan HL, Bhardwaj N, Liu Y, Marcellin P, Pan CQ, Shalimar, Buti M, Cox S, Parhy B, Zhou E, Martin R, Chang S, Lin L, Flaherty JF, Kitrinos KM, Gaggar A, Izumi N, Lim YS. No Resistance to Tenofovir Alafenamide Detected through 96 Weeks of Treatment in Patients with Chronic Hepatitis B Infection. Antimicrob Agents Chemother 2018;62:e01064-18. [PMID: 30038044 DOI: 10.1128/AAC.01064-18] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 5.5] [Reference Citation Analysis]
183 Nijhuis M, van Maarseveen NM, Boucher CA. Antiviral resistance and impact on viral replication capacity: evolution of viruses under antiviral pressure occurs in three phases. Handb Exp Pharmacol 2009;:299-320. [PMID: 19048205 DOI: 10.1007/978-3-540-79086-0_11] [Cited by in Crossref: 51] [Cited by in F6Publishing: 51] [Article Influence: 3.9] [Reference Citation Analysis]
184 Deng X, Li Q, Guo J. Dynamics of lamivudine-resistant hepatitis B virus strains in patients with entecavir rescue therapy. Virus Genes 2013;47:1-9. [DOI: 10.1007/s11262-013-0915-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
185 Ryu HH, Lee EY, Shin K, Choi IA, Lee YJ, Yoo B, Park MC, Park YB, Bae SC, Yoo WH. Hepatitis B virus reactivation in rheumatoid arthritis and ankylosing spondylitis patients treated with anti-TNFα agents: a retrospective analysis of 49 cases. Clin Rheumatol. 2012;31:931-936. [PMID: 22349880 DOI: 10.1007/s10067-012-1960-1] [Cited by in Crossref: 43] [Cited by in F6Publishing: 35] [Article Influence: 4.3] [Reference Citation Analysis]
186 Borroto-Esoda K, Miller MD, Arterburn S. Pooled analysis of amino acid changes in the HBV polymerase in patients from four major adefovir dipivoxil clinical trials. J Hepatol. 2007;47:492-498. [PMID: 17692425 DOI: 10.1016/j.jhep.2007.06.011] [Cited by in Crossref: 50] [Cited by in F6Publishing: 52] [Article Influence: 3.3] [Reference Citation Analysis]
187 Baldick CJ, Eggers BJ, Fang J, Levine SM, Pokornowski KA, Rose RE, Yu CF, Tenney DJ, Colonno RJ. Hepatitis B virus quasispecies susceptibility to entecavir confirms the relationship between genotypic resistance and patient virologic response. J Hepatol. 2008;48:895-902. [PMID: 18362040 DOI: 10.1016/j.jhep.2007.12.024] [Cited by in Crossref: 48] [Cited by in F6Publishing: 48] [Article Influence: 3.4] [Reference Citation Analysis]
188 Keeffe EB, Dieterich DT, Han SB, Jacobson IM, Martin P, Schiff ER, Tobias H. A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: 2008 Update. Clinical Gastroenterology and Hepatology 2008;6:1315-41. [DOI: 10.1016/j.cgh.2008.08.021] [Cited by in Crossref: 315] [Cited by in F6Publishing: 289] [Article Influence: 22.5] [Reference Citation Analysis]
189 Guo J, Li Q, Shi X, Zhang D, Zeng A, Feng T, Huang A. Dynamics of hepatitis B virus resistance to entecavir in a nucleoside/nucleotide-naïve patient. Antiviral Research 2009;81:180-3. [DOI: 10.1016/j.antiviral.2008.09.004] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 1.8] [Reference Citation Analysis]
190 Oketani M, Ido A, Nakayama N, Takikawa Y, Naiki T, Yamagishi Y, Ichida T, Mochida S, Onishi S, Tsubouchi H; Intractable Hepato-Biliary Diseases Study Group of Japan. Etiology and prognosis of fulminant hepatitis and late-onset hepatic failure in Japan: Summary of the annual nationwide survey between 2004 and 2009: Nationwide survey of FH and LOHF. Hepatology Research 2013;43:97-105. [DOI: 10.1111/j.1872-034x.2012.01105.x] [Cited by in Crossref: 91] [Cited by in F6Publishing: 35] [Article Influence: 10.1] [Reference Citation Analysis]
191 Chantratita W, Song KS, Pongthanapisith V, Thongbaiphet N, Angkanavin K, Nimse SB, Sonawane MD, Kim T. HBV/4DR 9G test and its comparison with INNO-LiPA HBV multi-DR test for the detection of drug-resistant Hepatitis B virus. J Virol Methods 2016;237:58-63. [PMID: 27581951 DOI: 10.1016/j.jviromet.2016.08.016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
192 Yamada N, Sugiyama R, Nitta S, Murayama A, Kobayashi M, Okuse C, Suzuki M, Yasuda K, Yotsuyanagi H, Moriya K, Koike K, Wakita T, Kato T. Resistance mutations of hepatitis B virus in entecavir-refractory patients. Hepatol Commun 2017;1:110-21. [PMID: 29404449 DOI: 10.1002/hep4.1022] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
193 Jun CH, Hong HJ, Chung MW, Park SY, Cho SB, Park CH, Joo YE, Kim HS, Choi SK, Rew JS. Risk factors for hepatocellular carcinoma in patients with drug-resistant chronic hepatitis B. World J Gastroenterol 2013; 19(40): 6834-6841 [PMID: 24187458 DOI: 10.3748/wjg.v19.i40.6834] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
194 Ferreira MS, Borges AS. [Advances in the treatment of hepatitis B]. Rev Soc Bras Med Trop 2007;40:451-62. [PMID: 17876470 DOI: 10.1590/s0037-86822007000400016] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
195 Tawada A, Kanda T, Yokosuka O. Current and future directions for treating hepatitis B virus infection. World J Hepatol 2015; 7(11): 1541-1552 [PMID: 26085913 DOI: 10.4254/wjh.v7.i11.1541] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.9] [Reference Citation Analysis]
196 Zhao FJ, Tang H, Zhang QH, Yang J, Davey AK, Wang JP. Salting-out homogeneous liquid-liquid extraction approach applied in sample pre-processing for the quantitative determination of entecavir in human plasma by LC-MS. J Chromatogr B Analyt Technol Biomed Life Sci 2012;881-882:119-25. [PMID: 22197609 DOI: 10.1016/j.jchromb.2011.12.003] [Cited by in Crossref: 46] [Cited by in F6Publishing: 37] [Article Influence: 4.2] [Reference Citation Analysis]
197 Kumar M, Sarin SK. Pharmacology, clinical efficacy and safety of lamivudine in hepatitis B virus infection. Expert Review of Gastroenterology & Hepatology 2014;2:465-95. [DOI: 10.1586/17474124.2.4.465] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
198 Fung J, Lai CL, Yuen MF. New paradigms for the treatment of chronic hepatitis B. J Gastroenterol Hepatol. 2008;23:1182-1192. [PMID: 18637060 DOI: 10.1111/j.1440-1746.2008.05400.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
199 Arrese E, Basaras M, Blanco S, Ruiz P, Cisterna R. Monitoring of therapy in patients with chronic hepatitis B virus. Eur J Gastroenterol Hepatol 2010;22:736-40. [PMID: 19550344 DOI: 10.1097/MEG.0b013e32832e0a44] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
200 Yotsuyanagi H, Koike K. Drug resistance in antiviral treatment for infections with hepatitis B and C viruses. J Gastroenterol 2007;42:329-35. [PMID: 17530355 DOI: 10.1007/s00535-007-2034-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
201 Keeffe EB, Dieterich DT, Pawlotsky JM, Benhamou Y. Chronic hepatitis B: Preventing, detecting, and managing viral resistance. Clin Gastroenterol Hepatol. 2008;6:268-274. [PMID: 18328434 DOI: 10.1016/j.cgh.2007.12.043] [Cited by in Crossref: 48] [Cited by in F6Publishing: 47] [Article Influence: 3.4] [Reference Citation Analysis]
202 Sheldon J, Sarmento E Castro R, Soriano V. [Resistance in hepatitis B virus]. Enferm Infecc Microbiol Clin 2008;26 Suppl 7:49-55. [PMID: 19100231 DOI: 10.1016/s0213-005x(08)76519-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
203 Ohkawa K, Takehara T, Kato M, Deguchi M, Kagita M, Hikita H, Sasakawa A, Kohga K, Uemura A, Sakamori R, Yamaguchi S, Miyagi T, Ishida H, Tatsumi T, Hayashi N. Supportive role played by precore and preS2 genomic changes in the establishment of lamivudine-resistant hepatitis B virus. J Infect Dis 2008;198:1150-8. [PMID: 18713056 DOI: 10.1086/591941] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
204 Min AD, Dienstag JL. Oral antivirals for chronic hepatitis B. Clin Liver Dis 2007;11:851-68, ix. [PMID: 17981232 DOI: 10.1016/j.cld.2007.08.003] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
205 Chien RN, Liaw YF. Nucleos(t)ide analogues for hepatitis B virus: strategies for long-term success. Best Pract Res Clin Gastroenterol 2008;22:1081-92. [PMID: 19187868 DOI: 10.1016/j.bpg.2008.11.003] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
206 Asselah T, Lada O, Boyer N, Martinot M, Marcellin P. [Treatment of chronic hepatitis B]. Gastroenterol Clin Biol. 2008;32:749-768. [PMID: 18775613 DOI: 10.1016/j.gcb.2008.07.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
207 Yu W, Goddard C, Clearfield E, Mills C, Xiao T, Guo H, Morrey JD, Motter NE, Zhao K, Block TM. Design, synthesis, and biological evaluation of triazolo-pyrimidine derivatives as novel inhibitors of hepatitis B virus surface antigen (HBsAg) secretion. J Med Chem. 2011;54:5660-5670. [PMID: 21786803 DOI: 10.1021/jm200696v] [Cited by in Crossref: 81] [Cited by in F6Publishing: 66] [Article Influence: 7.4] [Reference Citation Analysis]
208 Darweesh SK, Gad AA, Akroof K, ElLatif ZA. Entecavir and other nucleos(t)ide analogs prophylaxis in hepatitis B virus-related liver transplantation: long-term efficacy and safety. Eur J Gastroenterol Hepatol 2019;31:607-12. [PMID: 30724767 DOI: 10.1097/MEG.0000000000001377] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 2.3] [Reference Citation Analysis]
209 Suzuki Y, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Miyakawa Y, Kumada H. Efficacy of entecavir treatment for lamivudine-resistant hepatitis B over 3 years: Histological improvement or entecavir resistance? Journal of Gastroenterology and Hepatology 2009;24:429-35. [DOI: 10.1111/j.1440-1746.2008.05760.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
210 Walsh AW, Langley DR, Colonno RJ, Tenney DJ. Mechanistic characterization and molecular modeling of hepatitis B virus polymerase resistance to entecavir. PLoS One 2010;5:e9195. [PMID: 20169198 DOI: 10.1371/journal.pone.0009195] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 2.3] [Reference Citation Analysis]
211 Idilman R, Kaymakoglu S, Oguz Onder F, Ahishali E, Bektas M, Cinar K, Pinarbasi B, Karayalcin S, Badur S, Cakaloglu Y. A short course of add-on adefovir dipivoxil treatment in lamivudine-resistant chronic hepatitis B patients. J Viral Hepat. 2009;16:279-285. [PMID: 19222742 DOI: 10.1111/j.1365-2893.2009.01074.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.2] [Reference Citation Analysis]
212 Lee KS, Kim DJ; Guideline Committee of the Korean Association for the Study of the Liver. Management of Chronic Hepatitis B. Korean J Hepatol 2007;13:447. [DOI: 10.3350/kjhep.2007.13.4.447] [Cited by in Crossref: 41] [Cited by in F6Publishing: 32] [Article Influence: 2.7] [Reference Citation Analysis]
213 Boglione L, Cariti G, Di Perri G, D'Avolio A. Sequential therapy with entecavir and pegylated interferon in a cohort of young patients affected by chronic hepatitis B. J Med Virol. 2016;88:1953-1959. [PMID: 27017932 DOI: 10.1002/jmv.24534] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
214 Sayan M, Akhan SC, Meric M. Naturally occurring amino-acid substitutions to nucleos(t)ide analogues in treatment naive Turkish patients with chronic hepatitis B. J Viral Hepat 2010;17:23-7. [PMID: 19566788 DOI: 10.1111/j.1365-2893.2009.01149.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
215 Ismail AM, Sharma OP, Kumar MS, Eapen CE, Kannangai R, Abraham P. Virological response and antiviral resistance mutations in chronic hepatitis B subjects experiencing entecavir therapy: An Indian subcontinent perspective. Antiviral Research 2013;98:209-16. [DOI: 10.1016/j.antiviral.2013.02.012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
216 Tong CYW, Mullen JE, Wong T. Early hepatitis B virological rebound on entecavir through selection of lamivudine-associated mutations. Journal of Antimicrobial Chemotherapy 2009;64:875-7. [DOI: 10.1093/jac/dkp283] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
217 Gish RG, Lok AS, Chang T, de Man RA, Gadano A, Sollano J, Han K, Chao Y, Lee S, Harris M, Yang J, Colonno R, Brett–smith H. Entecavir Therapy for up to 96 Weeks in Patients With HBeAg-Positive Chronic Hepatitis B. Gastroenterology 2007;133:1437-44. [DOI: 10.1053/j.gastro.2007.08.025] [Cited by in Crossref: 258] [Cited by in F6Publishing: 238] [Article Influence: 17.2] [Reference Citation Analysis]
218 Ono A, Suzuki F, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Suzuki Y, Saitou S, Arase Y. Long-term continuous entecavir therapy in nucleos(t)ide-naïve chronic hepatitis B patients. J Hepatol. 2012;57:508-514. [PMID: 22659518 DOI: 10.1016/j.jhep.2012.04.037] [Cited by in Crossref: 109] [Cited by in F6Publishing: 103] [Article Influence: 10.9] [Reference Citation Analysis]
219 Oikonomou KG, Tsai E, Sarpel D, Dieterich DT. Liver Disease in Human Immunodeficiency Virus Infection. Clin Liver Dis 2019;23:309-29. [PMID: 30947879 DOI: 10.1016/j.cld.2018.12.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
220 Pallier C, Rodriguez C, Brillet R, Nordmann P, Hézode C, Pawlotsky JM. Complex dynamics of hepatitis B virus resistance to adefovir. Hepatology 2009;49:50-9. [PMID: 19065672 DOI: 10.1002/hep.22634] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 1.5] [Reference Citation Analysis]
221 Pérez V. Viral hepatitis: historical perspectives from the 20th to the 21st century. Arch Med Res. 2007;38:593-605. [PMID: 17613350 DOI: 10.1016/j.arcmed.2006.09.020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
222 Ghany MG, Doo EC. Antiviral resistance and hepatitis B therapy. Hepatology. 2009;49:S174-S184. [PMID: 19399794 DOI: 10.1002/hep.22900] [Cited by in Crossref: 142] [Cited by in F6Publishing: 140] [Article Influence: 10.9] [Reference Citation Analysis]
223 Abdelnabi Z, Saleh N, Baraghithi S, Glebe D, Azzeh M. Subgenotypes and mutations in the s and polymerase genes of hepatitis B virus carriers in the West Bank, palestine. PLoS One. 2014;9:e113821. [PMID: 25503289 DOI: 10.1371/journal.pone.0113821] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
224 Suzuki F, Toyoda J, Katano Y, Sata M, Moriyama M, Imazeki F, Kage M, Seriu T, Omata M, Kumada H. Efficacy and safety of entecavir in lamivudine-refractory patients with chronic hepatitis B: randomized controlled trial in Japanese patients. J Gastroenterol Hepatol. 2008;23:1320-1326. [PMID: 18554238 DOI: 10.1111/j.1440-1746.2008.05455.x] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 3.0] [Reference Citation Analysis]
225 Hadziyannis SJ. Treatment paradigms on hepatitis B e antigen-negative chronic hepatitis B patients. Expert Opin Investig Drugs. 2007;16:777-786. [PMID: 17501691 DOI: 10.1517/13543784.16.6.777] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 1.6] [Reference Citation Analysis]
226 Buster EH, Hansen BE, Lau GK, Piratvisuth T, Zeuzem S, Steyerberg EW, Janssen HL. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa. Gastroenterology. 2009;137:2002-2009. [PMID: 19737568 DOI: 10.1053/j.gastro.2009.08.061] [Cited by in Crossref: 265] [Cited by in F6Publishing: 251] [Article Influence: 20.4] [Reference Citation Analysis]
227 Chai H, Liang X, Li L, Zhao C, Gong P, Liang Z, Zhu W, Jiang H, Luo C. Identification of novel 5-hydroxy-1H-indole-3-carboxylates with anti-HBV activities based on 3D QSAR studies. J Mol Model 2011;17:1831-40. [DOI: 10.1007/s00894-010-0873-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
228 Jardi R, Rodriguez-Frias F, Tabernero D, Homs M, Schaper M, Esteban R, Buti M. Use of the novel INNO-LiPA line probe assay for detection of hepatitis B virus variants that confer resistance to entecavir therapy. J Clin Microbiol 2009;47:485-8. [PMID: 19052182 DOI: 10.1128/JCM.01678-08] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
229 Zoulim F, Radenne S, Ducerf C. Management of patients with decompensated hepatitis B virus associated cirrhosis. Liver Transpl 2008;14:S1-7. [DOI: 10.1002/lt.21615] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
230 Ismail AM, Sachithanandham J, Eapen CE, Kannangai R, Abraham P. Performance of LigAmp assay for sensitive detection of drug-resistant hepatitis B virus minor variants in comparison with standard nucleotide sequencing. Mol Diagn Ther 2014;18:655-63. [PMID: 25208639 DOI: 10.1007/s40291-014-0119-y] [Reference Citation Analysis]
231 Ozaras R, Khodor H, Yetim N, Unal UK, Demirhan YE, Gultekin G, Isal B. Monotherapy for hepatitis B infection: a review of treatment options. Expert Rev Anti Infect Ther 2015;13:1457-68. [PMID: 26414781 DOI: 10.1586/14787210.2015.1093934] [Reference Citation Analysis]
232 Yao G. Entecavir is a potent anti-HBV drug superior to lamivudine: experience from clinical trials in China. J Antimicrob Chemother. 2007;60:201-205. [PMID: 17556353 DOI: 10.1093/jac/dkm175] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 1.7] [Reference Citation Analysis]
233 Beloukas A, Geretti AM. Hepatitis B Virus Drug Resistance. In: Mayers DL, Sobel JD, Ouellette M, Kaye KS, Marchaim D, editors. Antimicrobial Drug Resistance. Cham: Springer International Publishing; 2017. pp. 1227-42. [DOI: 10.1007/978-3-319-47266-9_26] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
234 Choi YM, Lee SY, Kim BJ. Naturally occurring hepatitis B virus reverse transcriptase mutations related to potential antiviral drug resistance and liver disease progression. World J Gastroenterol 2018; 24(16): 1708-1724 [PMID: 29713126 DOI: 10.3748/wjg.v24.i16.1708] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
235 Lindh M, Uhnoo I, Bläckberg J, Duberg A, Friman S, Fischler B, Karlström O, Norkrans G, Reichard O, Sangfeldt P, Söderström A, Sönnerborg A, Weiland O, Wejstål R, Wiström J. Treatment of chronic hepatitis B infection: An update of Swedish recommendations. Scandinavian Journal of Infectious Diseases 2009;40:436-50. [DOI: 10.1080/00365540802154769] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
236 Jiang L, Jiang LS, Cheng NS, Yan LN. Current prophylactic strategies against hepatitis B virus recurrence after liver transplantation. World J Gastroenterol 2009; 15(20): 2489-2499 [PMID: 19468999 DOI: 10.3748/wjg.15.2489] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
237 Yokosuka O, Kurosaki M, Imazeki F, Arase Y, Tanaka Y, Chayama K, Tanaka E, Kumada H, Izumi N, Mizokami M, Kudo M. Management of hepatitis B: Consensus of the Japan Society of Hepatology 2009: Management of HBV: Consensus of JSH 2009. Hepatology Research 2011;41:1-21. [DOI: 10.1111/j.1872-034x.2010.00739.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
238 Wu I, Lai C, Han SB, Han K, Gordon SC, Chao Y, Tan C, Sievert W, Tanwandee T, Xu D, Neo B, Chang T. Efficacy of entecavir in chronic hepatitis B patients with mildly elevated alanine aminotransferase and biopsy-proven histological damage. Hepatology 2010;51:1185-9. [DOI: 10.1002/hep.23424] [Cited by in Crossref: 37] [Cited by in F6Publishing: 31] [Article Influence: 2.8] [Reference Citation Analysis]
239 Chaung KT, O'Brien C, Ha NB, Nguyen NH, Trinh HN, Nguyen MH. Alternative Therapies for Chronic Hepatitis B Patients With Partial Virological Response to Standard Entecavir Monotherapy. J Clin Gastroenterol. 2016;50:338-344. [PMID: 26646801 DOI: 10.1097/MCG.0000000000000455] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
240 Kim HJ, Cho YK, Jeon WK, Kim BI. Clinical characteristics of patients with chronic hepatitis B who developed genotypic resistance to entecavir: Real-life experience. Clin Mol Hepatol 2017;23:323-30. [PMID: 28870025 DOI: 10.3350/cmh.2017.0005] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
241 Jayakumar R, Joshi YK, Singh S. Laboratory evaluation of three regimens of treatment of chronic hepatitis B: tenofovir, entecavir and combination of lamivudine and adefovir. J Lab Physicians 2012;4:10-6. [PMID: 22923916 DOI: 10.4103/0974-2727.98664] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]